GI Partners to acquire majority interest in Clinical Ink

GI Partners will acquire a majority interest in Clinical Ink, Inc, a global clinical trial technology company. Existing Clinical Ink investor NovaQuest will continue to be a minority investor in the business.

Press Release

GI Partners, a leading private investment firm, announced today that it will acquire a majority interest in Clinical Ink, Inc., a global clinical trial technology company. In partnership with the company’s senior management team, GI Partners plans to accelerate Clinical Ink’s innovation in clinical trial workflow solutions. NovaQuest, an existing shareholder in Clinical Ink, will continue to be a minority investor in the business.

Headquartered in Horsham, PA, Clinical Ink offers data certainty from source to submission during clinical trials. The company’s Lumenis eSource clinical technology is a suite of solutions for capturing and integrating clinical trial electronic study data from sites, clinicians, and patients in real time. Through configurable direct data capture (DDC), electronic clinical outcome assessment (eCOA), electronic patient reported outcomes (ePRO), and eConsent modules, the company’s eSource Ecosystem has been deployed across 300 studies, in all Phases (I–IV).

“We are excited to partner with GI Partners to execute on our growth opportunities and innovate to serve our customers and partners,” said Ed Seguine, CEO of Clinical Ink. “The GI Partners team has proven experience investing in growing healthcare companies and will bring their expertise and operational excellence, as well as M&A skillsets, to partner with us on our journey. We look forward to the new partnership and continuing to extend our market-leading capabilities.”

Dave Kreter, Managing Director at GI Partners said, “We have been tracking the clinical trials technology space for several years and are attracted to the growth opportunity for the company’s eSource technology platform. Clinical Ink has distinguished itself through a commitment to innovation, differentiated technology solution, and dedication to service-first methodology. We are excited to partner with management to extend the company’s capabilities internationally and continue to develop new offerings.”

Mike Kirkman, Principal at GI Partners, commented, “We have been continually impressed with Clinical Ink’s ability to drive innovation within clinical trials and more safely and efficiently enable the drug development process. We look forward to working with Ed and his team to execute on the company’s growth strategy and continue to meet the evolving needs of the company’s customers and the sites and patients they serve.”

The transaction is expected to close in the third quarter of 2020, subject to customary closing conditions and regulatory approvals.

About Clinical Ink

Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lumenis™ eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules — a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source — naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress. Visit clinicalink.com.

About GI Partners

Founded in 2001, GI Partners is a private investment firm based in San Francisco, California. The firm has raised over $21 billion in capital from leading institutional investors around the world to invest in private equity, real estate, and data infrastructure strategies. The private equity team invests primarily in companies in the Healthcare, IT Infrastructure, Services, and Software sectors. The real estate team invests across a broad range of platforms and strategies. The data infrastructure team invests primarily in hard asset infrastructure businesses underpinning the digital economy. For more information on GI Partners and its entire portfolio, please visit www.gipartners.com.